Resistance patterns with tyrosine kinase inhibitors in melanoma: New insights

Current Opinion in Oncology

Volumn 24, Issue 2, 2012, Pages 150-154

  Dummer, Reinhard ^a   Flaherty, Keith T ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

molecular classification of melanoma; resistance; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SELUMETINIB; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB;

ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FATIGUE; FEVER; HEADACHE; HUMAN; MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; INDOLES; MELANOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84856890066     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834fca92     Document Type: Review

References (41)

1. Gibbons DL, Pricl S, Kantarjian H, et al. The rise and fall of gatekeeper mutations? The bcr-Abl1 t315i paradigm. Cancer 2012; 118:293-299.
2. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674. Outstanding summary of the current knowledge of cancer biology.
4. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68:664-673. (Pubitemid 351206741)
5. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147. (Pubitemid 41653105)
6. Garnett MJ, Marais R. Guilty as charged: B-raf is a human oncogene. Cancer Cell 2004; 6:313-319. (Pubitemid 39361432)
7. Omholt K, Grafstrom E, Kanter-Lewensohn L, et al. Kit pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17:3933-3942.
8. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of gnaq in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
9. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in gna11 in uveal melanoma. N Engl J Med 2010; 363:2191-2199.
10. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a raf inhibitor needs broad target blockade in braf-mutant melanoma. Nature 2010; 467:596-599. Comprehensive description of the development of a new kinase inhibitor.
11. Kefford RA, Arkenaua H, Brown MP, et al. Phase I/II study of gsk2118436, a selective inhibitor of oncogenic mutant braf kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28:abstract 8503.
12. Long GV, Kefford RF, Carr PJ, et al. Phase 1/2 study of gsk2118436, a selective inhibitor of v600 mutant (mut) braf kinase: Evidence of activity in melanoma brain metastases (mets). Ann Oncol 2010; 21:viii12.
13. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated braf in metastatic melanoma. N Engl J Med 2010; 363:809-819.
14. Ribas AK, Schuchter L, Gonzalez R, et al. Brim 2: An open-label, multicenter phase ii study of vemurafenib (plx4032, rg7204) in previously treated patients with brafv600e mutation-positive metastatic melanoma. J Clin Oncol 2011; 29:abstract 8575.
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med 2011; 364:2507-2516. Pivotal clinical trial demonstrating the impact of vemurafenib in advanced melanoma.
16. Poulikakos PI, Zhang C, Bollag G, et al. Raf inhibitors transactivate raf dimers and erk signalling in cells with wild-type braf. Nature 2010; 464:427-430.
17. Hatzivassiliou G, Song K, Yen I, et al. Raf inhibitors primewild-type raf to activate the mapk pathway and enhance growth. Nature 2010; 464:431-435.
18. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead braf and oncogenic ras cooperate to drive tumor progression through craf. Cell 2010; 140:209-221.
19. Dummer R, Rinderknecht J, Goldinger S. Photosensitivity during vemurafenib therapy is UVA-dependent. N Engl J Med (in press).
20. Pratilas CA, Taylor BS, Ye Q, et al. (v600e)braf is associated with disabled feedback inhibition of raf-mek signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009; 106:4519-4524.
21. Dummer R, Chapman PB, Sosman JA, et al. Azd6244 (arry-142886) vs temozolomide in patients with advanced melanoma: An open-label, randomized, multicenter, phase ii study. J Clin Oncol 2008; (Suppl):abstract 9033.
22. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral mek 1/2 inhibitor gsk1120212. J Clin Oncol 2010; 28:abstract 2503.
23. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in kit-mutated melanoma. J Clin Oncol 2008; 26:2046-2051.
24. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of kit in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340-4346. (Pubitemid 46630793)
25. Carvajal RD, Antonescu CR, Wolchok JD, et al. Kit as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327-2334.
26. Guo J, Si L, Kong Y, et al. Phase ii, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol 2011; 29:2904-2909.
27. Eichhoff OM, Zipser MC, Xu M, et al. The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: A case report. Melanoma Res 2010; 20:349-355.
28. Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? J Invest Dermatol 2010; 130:911-912. Sophisticated review on stemness in melanoma.
29. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141:583-594.
30. Hoek KS, Eichhoff OM, Schlegel NC, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68:650-656. (Pubitemid 351206739)
31. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010; 23:746-759.
32. Zipser MC, Eichhoff OM, Widmer DS, et al. A proliferative melanoma cell phenotype is responsive to raf/mek inhibition independent of braf mutation status. Pigment Cell Melanoma Res 2011; 24:326-333.
33. Johannessen CM, Boehm JS, Kim SY, et al. Cot drives resistance to raf inhibition through map kinase pathway reactivation. Nature 2010; 468:968-972. Important report on a new resistance mechanism in melanomas during BRAF inhibition.
34. Kim KT, Chapman PB, Sosman JA, et al. Pattern and outcome of disease progression in phase i study of vemurafenib in patients with metastatic melanoma. J Clin Oncol 2011; 29:abstract 8519.
35. McArthur GA, Chapman PB, Flaherty KT, et al. Molecular analyses from a phase i trial of vemurafenib to study mechanism of action and resistance in repeated biopsies from braf mutation-positive metastatic melanoma patients. J Clin Oncol 2011; 29:abstract 8502.
36. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to b-raf(v600e) inhibition by rtk or n-ras upregulation. Nature 2010; 468:973-977. Important report on a new resistance mechanism in melanomas during BRAF inhibition.
37. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to raf inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-3096. Important report on a new resistance mechanism in melanomas during BRAF inhibition.
38. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to braf inhibitors mediated by a raf kinase switch in melanoma can be overcome by cotargeting mek and igf-1r/pi3k. Cancer Cell 2010; 18:683-695. Important report on a new resistance mechanism in melanomas during BRAF inhibition.
39. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic braf in metastatic melanoma. J Clin Oncol 2011; 29:1239-1246. A demonstration of the clinical impact of a single mutation in stage IV melanoma.
40. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. Genome Res 2010; 20:413-427. The first description of the transcriptome in melanoma.
41. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-196.